BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2025 5:29:08 AM | Browse: 44 | Download: 62
 |
Received |
|
2025-01-07 08:38 |
|
Peer-Review Started |
|
2025-01-09 00:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-24 10:24 |
|
Revised |
|
2025-04-05 14:27 |
|
Second Decision |
|
2025-06-27 07:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-07-01 09:28 |
|
Articles in Press |
|
2025-07-01 09:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-07-06 19:35 |
|
Typeset the Manuscript |
|
2025-08-11 10:05 |
|
Publish the Manuscript Online |
|
2025-08-21 05:29 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Advances in mesenchymal stem cell therapy for lupus nephritis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Lin Liu, Tapas Ranjan Behera, Qiao-Jun Wang and Quan-Quan Shen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Zhejiang Province |
LY23H050005 |
| Zhejiang Medical Technology Project |
2020KY439, 2022RC009, 2024KY645, 2024KY697 |
|
| Corresponding Author |
Quan-Quan Shen, Associate Professor, MD, Department of Nephrology, Zhejiang Provincial People’s Hospital Bijie Hospital, No. 112 Guanghui Road, Bijie 551700, Guizhou Province, China. spring198457@sina.com |
| Key Words |
Systemic lupus erythematosus; Bone marrow-derived mesenchymal stem cells; Umbilical cord-derived mesenchymal stem cells; Adipose tissue-derived mesenchymal stem cells; Dental tissue-derived mesenchymal stem cells; Lupus nephritis; Immunoregulation; Clinical trials |
| Core Tip |
Lupus nephritis (LN) is one of the most common and serious complications of systemic lupus erythematosus. Mesenchymal stem cell (MSC) therapy has received extensive attention in LN. This article summarizes the sources of MSCs, the mechanisms of MSC therapy in the treatment of LN and the results of clinical trials. MSC therapy for LN shows great potential, but still requires the support of large-scale clinical trials. |
| Publish Date |
2025-08-21 05:29 |
| Citation |
<p>Liu L, Behera TR, Wang QJ, Shen QQ. Advances in mesenchymal stem cell therapy for lupus nephritis. <i>World J Stem Cells</i> 2025; 17(8): 104930</p> |
| URL |
https://www.wjgnet.com/1948-0210/full/v17/i8/104930.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v17.i8.104930 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
